Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis plans Chinese R&D center
Research and development activities at the site will initially focus on addressing urgent medical needs in China and Asia, particularly infectious causes of cancer endemic to the region,
Research and development activities at the site will initially focus on addressing urgent medical needs in China and Asia, particularly infectious causes of cancer endemic to the region,
The trial includes small cell lung cancer (SCLC) patients with who are platinum-resistant or refractory and who have progressed within six months after receiving first-line therapy. Picoplatin is
Madaus has marketed trospium chloride throughout Europe for over 20 years. “We believe the position Madaus holds in the European market offers us the best opportunity to successfully
Plan B will be available over-the counter to women over the age of 18, and will still be prescription-only for women 17 and younger. The new version replaces
Geron’s therapeutic cancer vaccine, GRNVAC1, triggers an immune response against the universal cancer antigen, telomerase, and uses the LAMP sequence to enhance that immune response. The LAMP technology
Kos Pharmaceuticals' two lead products are Niaspan, an extended-release niacin product that raises HDL, or good cholesterol levels; and Advicor, a Niaspan/lovastatin combination product that treats patients with
The biologics license application (BLA) filing is based on, and contains data from a phase III clinical trial. The trial measured and demonstrated the equivalence of topical human
Numax met its primary endpoint of non-inferiority by reducing the incidence of hospitalizations caused by respiratory syncytial virus (RSV) in infants at high risk by 26% when compared
The FDA has issued a letter stating it will only approve Entereg if the company provides 12-month safety data, including analysis of serious cardiovascular events from an ongoing
The trials were designed to evaluate Erbitux in patients with metastatic colorectal cancer. The first phase III trial compared Erbitux plus best supportive care to best supportive care